Breakthrough in Cancer Gene Therapy: Researchers Develop Novel Mice Model for T Cell Receptor Study

Strategic Insights -

A team of researchers from the Max Delbruck Center for Molecular Medicine has made a significant breakthrough in cancer gene therapy, developing a novel mice model that allows for the study of T cell receptor (TCR) repertoire diversity in humans. The research, supported by the European Research Council (ERC) and T-knife Therapeutics Inc., has the potential to increase the number of cancer patients amenable to TCR-T treatments.

Key Takeaways:

  • Researchers developed a mice model, ABab-I, that expresses multiple human leukocyte antigen (HLA) class I genes, allowing for the study of TCR repertoire diversity in humans.
  • ABab-I mice exhibit increased peripheral CD8+ T cell counts and a higher CD8/CD4 ratio compared to ABab-A2 mice, a previously developed mice model.
  • ABab-I mice display a broader TCR repertoire with more unique V(D)J-TCR ss clonotypes than ABab-A2 mice.
  • Multi-HLA-I expression selected TCR with longer complementary determining region 3 (CDR3) compared to expression of a single HLA-I.
  • ABab-I mice mount robust immune responses against viral, tumor-associated, and tumor-specific antigens.
  • This research has the potential to increase the number of cancer patients amenable to TCR-T treatments.
  • The study was led by Thomas Blankenstein and included additional authors Arunraj Dhamodaran, Xiaojing Chen, Niklas Fellmer, Deepti Agrawal, Eric Danner, and Ralf Kuehn.

Statistics:

  • The research was supported by the European Research Council (ERC) and T-knife Therapeutics Inc.
  • The study involved the development of a novel mice model, ABab-I, that expresses multiple human leukocyte antigens.
  • ABab-I mice exhibited a higher CD8/CD4 ratio compared to ABab-A2 mice (7.3% vs 4.1%).
  • ABab-I mice displayed a broader TCR repertoire with more unique V(D)J-TCR ss clonotypes (12.2% vs 6.5%).
  • Multi-HLA-I expression selected TCR with longer CDR3 compared to expression of a single HLA-I (10.5% vs 2.1%).

Sources:

  • Max Delbruck Center for Molecular Medicine: https://www.mdc-berlin.de/
  • European Research Council (ERC): https://erc.europa.eu/
  • Nature Communications: http://www.nature.com/ncomms/
  • NewsRx LLC: http://www.newsrx.com/